Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind trial of TA-5538 in overactive bladder
2005-005457-22Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TA-5538 in overactive bladder (OAB) (3 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Mean number of micturitions per day. Started Feb 2006; status: completed.
02
Drugs
TA-5538
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-005457-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005457-22.